KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Gains from Investment Securities (2018 - 2025)

Castle Biosciences' Gains from Investment Securities history spans 7 years, with the latest figure at $338000.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 85.53% year-over-year to $338000.0; the TTM value through Dec 2025 reached $119000.0, down 80.4%, while the annual FY2025 figure was $119000.0, 80.4% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $338000.0 at Castle Biosciences, up from -$263000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.6 million in Q1 2022 and bottomed at -$20.4 million in Q2 2022.
  • The 5-year median for Gains from Investment Securities is $5500.0 (2021), against an average of -$957166.7.
  • The largest YoY upside for Gains from Investment Securities was 7863.64% in 2022 against a maximum downside of 56561.11% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $69000.0 in 2021, then tumbled by 523.19% to -$292000.0 in 2022, then crashed by 283.22% to -$1.1 million in 2023, then tumbled by 58.71% to -$1.8 million in 2024, then skyrocketed by 119.03% to $338000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Gains from Investment Securities are $338000.0 (Q3 2025), -$263000.0 (Q2 2025), and $44000.0 (Q1 2025).